Breast Cancer Profile among Patients with a History of Chemoprevention

Table 1

Clinical characteristics.

Variables	Primary (, 1%)	%		Secondary (, 5%)	%		Control (, 94%)	%
Median age (years)	59 (46–76)		0.39	66 (39–85)		<0.0001	59 (22–95)
Family history of breast cancer
Yes	7	39	0.17	41	35	0.01	573	25
No	11	61		76	65		1722	75
Genetic testing
Yes	5	38	1.00	59	64	<0.0001	633	40
No	8	62		33	36		944	60
Not reported	5	—		25	—		718	—
BRCA 1,2
Positive	3	60	0.008	6	10	0.82	60	9
Negative	2	40		53	90		573	91
Atypical hyperplasia (AH)
Yes	8	44	<0.0001	6	5	0.02	38	2
No	10	56		111	95		2257	98
Lobular carcinoma in situ (LCIS)
Yes	4	22	<0.0001	1	1	1.00	21	1
No	14	78		116	99		2274	99
Clinical stage of breast cancer
0, I	14	77	0.61	94	81	0.02	1605	70
II, III, IV	4	23		23	19		690	30
Histology
DCIS (including DCIS w/microinv)	8	44		31	27		530	23
IDC	8	44	0.15	67	57	0.64	1437	62
ILC	1	6		13	11		222	10
Other invasive	1	6		6	5		106	5
Estrogen receptor
Positive	16	89	1.00	83	73	0.004	1901	84
Negative	2	11		30	27		349	16
Unknown	0	—		4	—		45	—
Progesterone receptor
Positive	11	65	0.59	68	60	0.01	1615	72
Negative	6	35		45	40		632	28
Unknown	1	—		4	—		48	—
HER2/neu
Positive	1	10	1.00	12	14	0.42	220	13
Negative	9	90		72	86		1501	85
Equivocal	0	0		0	0		39	2
Unknown/NA	8	—		33	—		535	—
Triple negative breast cancer
Yes	1	6	1.00	12	10	0.28	170	7
No	17	94		105	90		2125	93

Fisher’s Exact Test for primary versus nonchemoprevention groups.
Fisher’s Exact Test for secondary versus nonchemoprevention groups.